A $123 million financing has been raised for US-based Sling Therapeutics Inc, equipping it to carry out a Phase 3 trial of a candidate therapy for thyroid eye disease – an autoimmune disorder that can affect vision. Announced on 16 September, the Series C round was led by Forbion Capital Partners of the Netherlands with participation from new investor Sectoral Asset Management of Canada and existing investor TPG Life Sciences Innovations of the US.
GSK Plc is to pay up to $750 million to acquire a new asset for multiple myeloma – its latest move to expand its portfolio for blood cancers. The asset is a trispecific T cell engager, an engineered antibody linking the body’s immune cells directly to antigens on cancer cells. There are currently no approved trispecific T cell engagers, but authorisations have been granted to bispecific T cell engagers, a simpler version of the same therapy. Announced on 15 September, the deal includes an undisclosed upfront fee and milestone payments.
France-based ophthalmology company Nicox SA announced an extension of its cash runway on 2 September ahead of regulatory reviews in both the US and China for its lead product NCX 470 (bimatoprost grenod) for two ocular conditions. As of 31 August, the company’s estimated cash and cash equivalents was €8.4 million compared with €4.1 million on 31 December 2025. The company said the cash position will carry it through the regulatory decision period which, if successful, would generate new revenue.
US-based ReCode Therapeutics Inc has strengthened its ties with the Cystic Fibrosis Foundation as it progresses an experimental messenger RNA (mRNA) therapy for the disease through the clinic. Simultaneously, it promoted Heather Clark on 1 July to the role of chief executive from vice president and head of the company’s cystic fibrosis franchise. Ms Clark joined ReCode in 2022. She has nearly 30 years of experience in rare disease drug development of which more than half were spent at Vertex Pharmaceuticals Inc, developer of five marketed cystic fibrosis products.
Switzerland-based Vaderis Therapeutics AG has raised $152 million from a Series B financing round to support development of a small molecule drug, engasertib, for a rare vascular disease for which no treatments are currently approved. The disease is hereditary haemorrhagic telangiectasia (HHT), a genetic disorder affecting the vasculature, which manifests in nose bleeds, anaemia, and visceral arteriovenous malformations (AVMs) AVMs are tangles of blood vessels that can cause internal bleeding and organ damage.
On 4 August, the European Commission completed the final legal steps for the launch of the Scaleup Europe Fund, a public-private partnership that will invest in European companies with potential to compete globally in advanced technologies. The fund is being launched with a target capital of €5 billion. The fund’s first investment, a day after launch, was in the Finnish space technology company ICEYE.
Ireland-based Jazz Pharmaceuticals Plc is to expand its presence in the epilepsy field with the acquisition of privately-held Actio Biosciences of San Diego, US, which has a clinical-stage product for a rare genetic epilepsy. In parallel, Jazz will take a minority stake in a spin-out of Actio, which will develop a cluster of rare disease products.
argenx SE is to expand its immunology portfolio with the acquisition of Forte Biosciences Inc of Dallas, Texas, US, whose lead product is being investigated in two autoimmune diseases. The Netherlands-based company is to pay $77 per share in cash for the company, representing an equity value of about $2.2 billion – it’s largest deal to date. Both companies are listed on the US Nasdaq exchange.
Scribe Therapeutics Inc, a company co-founded by the Nobel laureate Jennifer Doudna, has raised $128.7 million in an initial public offering on the US Nasdaq market – one of a growing number of biotech companies to go public this year. The funds will be used to advance the company’s lead programme for patients with elevated low-density lipoprotein cholesterol (LDL-C) through Phase 1, and to develop two preclinical projects for cardiovascular and metabolic disorders.
Venture-capital backed Mission Therapeutics Ltd is to divest a clinical asset for the treatment of acute kidney injury to Australia-based Dimerix Ltd providing it with $292 million in non-dilutive capital. This will enable it to pursue its priority treatment for Parkinson’s disease and other possible central nervous system disorders. Announced on 17 July, the deal will also deliver up to double-digit tiered royalties to Mission should the kidney product, MTX652, reach the market. It is currently poised to enter Phase 2. The small molecule drug, MTX325, for Parkinson’s is in Phase 1.